Randomized double-blind trial reports safety and efficacy of canakinumab in alcohol-related hepatitis, highlighting targeted interleukin-1 inhibition.
Short-term mortality in alcohol-related hepatitis (AH) is high, and no current therapy results in durable benefit. A role for interleukin (IL)-1β has been demonstrated in the pathogenesis of alcohol-induced steatohepatitis. This study explored the safety and efficacy of canakinumab (CAN), a monoclonal antibody targeting IL-1β, in the treatment of patients with AH.
No takes yet. Share an insight, caveat, or question.
Vergis et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: